In some cases a party that has branded goods manufactured in China
for export ("OEM" manufacturing) holds the relevant
trademark in the country of destination, while another party holds
the relevant trademark in China. This raises the question whether
this could result in an infringement of the trademark rights of the
holder of the Chinese trademark.
Recently, the Supreme People's Court of China held that OEM
manufacturing solely for export was not "use" under
Chinese trademark laws as the exporter only engaged Chinese OEM
manufacturers and did not distribute nor advertise the branded
products in China. Even though the Supreme Court's opinion is
not codified in statutory laws, it provides some degree of clarity
and guidance to lower courts and administrative authorities as to
how to deal with this legal issue in future practice.
To improve their position based on this recent Supreme Court
ruling, it will help non-Chinese trademark right holders if they
expressly provide in agreements with their OEM manufacturers that
the manufactured products are made solely for export. In addition,
they should provide proof to the OEM manufacturers that they
legitimately possess the trademark rights in the country of
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Patents Act 1970, along with the Patents Rules 1972, came into force on 20th April 1972, replacing the Indian Patents and Designs Act 1911. The Patents Act was largely based on the recommendations of the Ayyangar Committee Report headed by Justice N. Rajagopala Ayyangar. One of the recommendations was the allowance of only process patents with regard to inventions relating to drugs, medicines, food and chemicals.
Lupin Limited is an innovation led transnational pharmaceutical company which develops and offers a wide range of branded & generic formulations, biotechnology products...
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).